Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENLIUS (02696.HK): HLX07 International Multi-center Phase 2/3 Clinical Study Completes First Patient Dosing in China
Recommend 2 Positive 1 Negative 0 |
||||
|
||||
|
HENLIUS (02696.HK) announced that its self-developed pimurutamab HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) (HLX07), in combination with Hansizhuang and chemotherapy, versus placebo plus Hansizhuang or pembrolizumab and chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC), has completed first patient dosing in China for its international multi-center Phase 2/3 clinical study. The primary objective of the study is to evaluate the efficacy of HLX07 in combination with Hansizhuang and chemotherapy versus placebo plus Hansizhuang or pembrolizumab and chemotherapy as first-line treatment in patients with advanced sqNSCLC. Secondary objectives include assessing the safety, pharmacokinetic profile and immunogenicity of HLX07 in combination with Hansizhuang and chemotherapy, as well as evaluating the relationship between EGFR expression, PD-L1 expression in tumor tissues and clinical efficacy. (sl/da) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
